341 related articles for article (PubMed ID: 18274992)
1. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
Santos MA; Gama S; Gil M; Gano L
Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
[TBL] [Abstract][Full Text] [Related]
2. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.
Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA
J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126
[TBL] [Abstract][Full Text] [Related]
3. Combined chelation of bi-functional bis-hydroxypiridinone and mono-hydroxypiridinone: synthesis, solution and in vivo evaluation.
Gama S; Gil M; Gano L; Farkas E; Amélia Santos M
J Inorg Biochem; 2009 Feb; 103(2):288-98. PubMed ID: 19091421
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
5. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
6. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
7. New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation.
Grazina R; Gano L; Sebestík J; Amelia Santos M
J Inorg Biochem; 2009 Feb; 103(2):262-73. PubMed ID: 19062099
[TBL] [Abstract][Full Text] [Related]
8. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
9. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
10. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
Liu G; Men P; Kenner GH; Miller SC; Bruenger FW
Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
12. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
Tubafard S; Fatemi SJ
Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
15. Long term deferiprone chelation therapy.
Hoffbrand VA; Wonke B
Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
[No Abstract] [Full Text] [Related]
16. Overview of iron chelation therapy with desferrioxamine and deferiprone.
Cappellini MD; Musallam KM; Taher AT
Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
[TBL] [Abstract][Full Text] [Related]
17. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
18. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
19. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Kalinowski DS; Richardson DR
Chem Res Toxicol; 2007 May; 20(5):715-20. PubMed ID: 17402750
[TBL] [Abstract][Full Text] [Related]
20. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
